Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report

Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the abnormal accumulation of surfactant-derived substances in the lungs. To the best of our knowledge, the successful treatment of metastatic renal cell carcinoma in patients with PAP has not been reported. Here, we describe suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Nobuaki, Hasumi, Masaru, Muramatsu, Kazumichi, Tsuji, Yusuke, Takaku, Youtarou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436122/
https://www.ncbi.nlm.nih.gov/pubmed/34540590
http://dx.doi.org/10.1016/j.eucr.2021.101843
Descripción
Sumario:Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the abnormal accumulation of surfactant-derived substances in the lungs. To the best of our knowledge, the successful treatment of metastatic renal cell carcinoma in patients with PAP has not been reported. Here, we describe such treatment of a patient via avelumab plus axitinib therapy. After four courses of treatment, computed tomography showed size reduction of the pulmonary metastatic nodule and improvement of PAP. This study highlights that avelumab plus axitinib therapy is a safe and effective treatment option for metastatic renal cell carcinoma, even in patients with PAP.

Ejemplares similares